Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Evolus, Inc.

Market Cap 437M 381M 353M 330M 619M 41.2B 623M 4.18B 1.62B 20.28B 1.64B 1.6B 70.41B P/E 2026 *
-13.3x
P/E 2027 * -45.2x
Enterprise Value 564M 491M 455M 426M 799M 53.18B 804M 5.4B 2.09B 26.18B 2.12B 2.07B 90.89B EV / Sales 2026 *
1.71x
EV / Sales 2027 * 1.47x
Free-Float
83.36%
Yield 2026 *
-
Yield 2027 * -
1 day-1.63%
1 week-1.49%
Current month+1.07%
1 month+0.61%
3 months+42.89%
6 months-6.22%
Current year-0.30%
1 week 6.53
Extreme 6.53
7
1 month 5.95
Extreme 5.95
7
Current year 3.86
Extreme 3.86
7
1 year 3.86
Extreme 3.86
10.2
3 years 3.86
Extreme 3.86
17.82
5 years 3.86
Extreme 3.86
17.82
10 years 2.85
Extreme 2.85
39.5
Manager TitleAgeSince
Chief Executive Officer 48 06/05/2018
Director of Finance/CFO 48 08/09/2025
Chief Operating Officer - 01/09/2022
Director TitleAgeSince
Chairman 63 01/01/2018
Director/Board Member 71 12/02/2018
Director/Board Member 48 06/05/2018
Date Insider Type Main position Quantity % Market Cap.
03-20Sell

Chief Technology Officer

3,119 0.0048%
03-20Sell

Chief Executive Officer

13,669 0.0211%
03-16Fiscal year

Chief Executive Officer

251,698 0.3891%
Change 5-day change 1-year change 3-year change Capi.($)
-1.63%-1.49%-28.56%-18.15% 437M
-1.21%-3.04%+44.03%+143.07% 980B
-2.48%-5.18%+52.47%+39.15% 550B
-2.14%-4.94%+16.83%+57.08% 382B
+0.25%-3.09%+23.33%+16.04% 316B
+0.61%-1.69%+27.35%+13.73% 272B
+0.22%-3.10%+24.67%+30.49% 268B
+4.59%+1.98%-38.43%-46.26% 199B
-1.19%-4.95%+16.68%+47.69% 182B
-1.35%-1.46%+14.06%+59.26% 154B
Average -0.43%-2.53%+15.24%+34.21% 330.28B
Weighted average by Cap. -0.78%-3.68%+29.48%+63.30%

Financials

2026 *2027 *
Net sales 330M 288M 267M 250M 468M 31.18B 471M 3.17B 1.23B 15.35B 1.24B 1.21B 53.29B 388M 338M 313M 293M 550M 36.58B 553M 3.71B 1.44B 18.01B 1.46B 1.42B 62.52B
Net income -33.31M -29.04M -26.9M -25.18M -47.22M -3.14B -47.51M -319M -124M -1.55B -125M -122M -5.37B -10.56M -9.21M -8.53M -7.98M -14.97M -997M -15.06M -101M -39.21M -491M -39.64M -38.79M -1.7B
Net Debt 127M 111M 103M 96M 180M 11.98B 181M 1.22B 472M 5.9B 477M 466M 20.48B 132M 115M 107M 99.78M 187M 12.46B 188M 1.26B 490M 6.13B 495M 485M 21.29B
Logo Evolus, Inc.
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
Employees
350
Date Price Change Volume
18/06/26 6.630 $ -1.63% 1,101,794
17/06/26 6.740 $ +1.66% 1,040,108
16/06/26 6.630 $ -1.78% 806,705
15/06/26 6.750 $ +0.30% 904,163
12/06/26 6.730 $ +3.38% 635,634
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
6.630USD
Average target price
14.67USD
Spread / Average Target
+121.22%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EOLS Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!